Skip to main content
. 2022 Nov 22;4:100140. doi: 10.1016/j.crphar.2022.100140

Table 1.

Characteristics of the studies included in the meta-analysis.

Studies Jadad score (/5) MYOINOSITOL group
Control group
Number (n) Age (years (mean ​± ​SD or (extrem values))) BMI (kg/m2 (mean ​± ​SD or (extrem values))) Intervention Number (n) Age (years (mean ​± ​SD or (extrem values))) BMI (kg/m2 (mean ​± ​SD or (extrem values))) Intervention
D'Anna R 2012 (D'Anna et al., 2012) 1 44 29.2 ​± ​3.8 26.2 ​± ​5.8 MYO 2g ​+ ​FA 200 ​μg 2/day 54 30.6 ​± ​4.2 24.7 ​± ​3.9 FA 200 ​μg 2/day
D'Anna R 2013 (D'Anna et al., 2013) 3 110 31.0 ​± ​5.3 22.8 ​± ​3.1 MYO 2g ​+ ​FA 200 ​μg 2/day 110 31.6 ​± ​5.6 23.6 ​± ​3.1 FA 200 ​μg 2/day
Matarelli 2013 (Matarrelli et al., 2013) 3 39 33.0 ​± ​4.9 23.5 ​± ​3.4 MYO 2g ​+ ​FA 200 ​μg 2/day 36 33.8 ​± ​4.7 24.7 ​± ​42 FA 200 ​μg 2/day
D'Anna R 2015 (D'Anna et al., 2015) 3 110 31.9 (18-44) 33.8 (30.0-46.9) MYO 2g ​+ ​FA 200 ​μg 2/day 110 31.7 (19-43) 33.8 (30.0-46.0) FA 200 ​μg 2/day
Santamaria et al., 2016 (Santamaria et al., 2016) 3 110 32.1 ​± ​4.8 26.9 ​± ​1.3 MYO 2g ​+ ​FA 20 ​μg 2/day 110 32.7 ​± ​5.3 27.1 ​± ​1.3 FA 200 ​μg 2/day
Farren et al., 2017 (Farren et al., 2017) 3 120 31.1 ​± ​5.1 26.0 ​± ​5.3 MYO 1100 ​mg ​+ ​DCI 27.6 ​mg ​+ ​FA 400 ​μg 1/day 120 31.5 ​± ​5.0 26.2 ​± ​5.5 FA 400 ​μg 1/day
D'Ell Edera 2017 (Dell’Edera et al., 2017) 2 43 32.5 ​± ​3.6 25.6 ​± ​4.0 MYO 1750 ​mg ​+ ​DCI 250 ​mg ​+ ​zinc 12,5 ​mg ​+ ​methylsulfonylmethane 1/day 40 32.3 ​± ​3.8 26.9 ​± ​3.1 FA 400 ​μg 1/day
Celentano et al., 2020 (Celentano et al., 2020) 3 60 33.1 ​± ​4.9 23.5 ​± ​3.4 MYO 2g ​+ ​FA 200 ​μg 2/day 40 33.9 ​± ​4.9 24.4 ​± ​4.1 FA 200 ​μg 2/day
40 34.1 ​± ​4.2 23.5 ​± ​4.6 MYO 1100 ​mg ​+ ​DCI 27.6 ​mg ​+ ​FA 400 ​μg 1/day
Vitale 2020 (Vitale et al., 2021) 3 125 27.8 ​± ​6.0 27.0 ​± ​1.5 MYO 2g ​+ ​FA 200 ​μg 2/day 125 27.9 ​± ​4.9 26.7 ​± ​1.6 FA 200 ​μg 2/day

BMI: body mass index; d: day; DCI: 1D-chiro-inositol; FA: folic acid; MYO: myoinositol; SD: standard deviations.